Recursion Pharmaceuticals (RXRX) Net Cash Flow Growth (3y) (2023 - 2026)
Recursion Pharmaceuticals (RXRX) Net Cash Flow Growth (3y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 89.97% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -13.44% |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 33.37% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Recursion Pharmaceuticals | 1.71 Bn | 1.05 Bn | -6.02 Mn | -3.43% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.43% |
| Dec 31, 2025 | -3.60% |
| Sep 30, 2025 | 452.33% |
| Jun 30, 2025 | 31.73% |
| Mar 31, 2025 | -34.68% |
| Dec 31, 2024 | 52.65% |
| Sep 30, 2024 | 41.63% |
| Jun 30, 2024 | -25.29% |
| Mar 31, 2024 | -25.55% |
| Dec 31, 2023 | -33.65% |
| Sep 30, 2023 | -27.94% |
| Jun 30, 2023 | -58.99% |
| Mar 31, 2023 | -83.08% |